SC Launch Company, KIYATEC Inc., Receives Grainger Grant Funding to Support SC and University of Southern California Research Business Wire COLUMBIA, S.C. -- March 27, 2013 SCRA Technology Ventures’ SC Launch Program today announced that KIYATEC, Inc. recently received a $30,000 Grainger Foundation Frontiers of Engineering Grant. The grant was jointly awarded to KIYATEC CEO Matthew Gevaert and the University of Southern California’s Andrea Armani to further the team’s work to more accurately understand and predict human response to drugs. KIYATEC, based in Greenville, SC, has received $575,000 in SC Launch investments over the last four years. Using technologies developed and licensed from Clemson University, the company has rapidly grown since its inception in 2005, moving into Greenville Health System’s Institute for Translational Oncology Research in 2011. KIYATEC’s location inside the hospital gives the company a significant advantage in its mission to provide meaningful data that links drug performance to patient outcomes. By doing so, KIYATEC will benefit patients and save costs in both healthcare and drug development. “This grant is the first step in a new, exciting collaboration,” said Gevaert. “We are hopeful that the data we'll produce will lead to further funding for this type of platform integration, an aspect of our quest to create ever smarter, ever better cell culture systems.” “The Grainger Grant is but one example of the national recognition KIYATEC is receiving,” said SCRA CEO Bill Mahoney. “The SCRA Technology Ventures and SC Launch teams congratulate Matt and KIYATEC on this achievement. Our SC Launch companies continue to grow and produce quality technologies that are advancing products and processes to improve lives. A second example of such national recognition is KIYATEC’s upcoming podium presentation at the annual meeting of the American Association for Cancer Research in Washington, DC on April 7th. The company will present data on its ability to predict the effectiveness of anti-cancer drugs before they are used in patients during clinical trials. We look forward to KIYATEC’s future successes and partnerships.” The Grainger Foundation, an independent, private foundation based in Lake Forest, Illinois, was established in 1949 by William W. Grainger, founder of W.W. Grainger, Inc. Grainger Grants provide seed funding for U.S- based institutions to enable further pursuit of important new interdisciplinary research and projects. About SCRA and SCRA Technology Ventures http://www.scra.org/ SCRA Technology Ventures helps innovative companies grow and develop new technologies, creating jobs and advancing the Knowledge Economy throughout South Carolina. This SCRA business sector provides support and mentoring through its flagship SC Launch program to early stage, start-up technology companies. Since 2006, SCRA has deployed over $59 million in funding and infrastructure to support over 271 high -tech, early-stage enterprises, and has directly invested over $13 million in South Carolina start-ups, attracting over $212 million in private investment. SCRA Technology Ventures also supports commercialization and growth by facilitating the transfer of intellectual property and accelerating the transition of inventions to the marketplace. Additionally, SCRA Technology Ventures invests in more established technology companies through its Stage 2 affiliate. Multiple economic impact studies show SCRA's cumulative output on South Carolina's economy to be over $15.3 billion, and that the company has helped create approximately 15,000 technology-related jobs in the state, with annual wages averaging between $55,000 and $77,000. About KIYATEC KIYATEC provides advanced 3D cell-based assays for preclinical screening of small molecules and biologics to assess toxicity and efficacy. As a contract research service provider, we deploy physiologically relevant cell culture techniques to more accurately predict anti-cancer efficacy, immune-related hepatotoxicity, and cell response to implantable biomaterials. KIYATEC offices and labs are located within the Institute for Translational Oncology Research (ITOR) and co-located with the ITOR Clinical Research Unit on the main campus of the Greenville Health System, the 13th largest public hospital system in the US. We utilize primary sourced cells and tissues, advanced proteomics, imaging and other analytical capabilities to provide valuable data and insight to meet the needs of our pharmaceutical, biotechnology and medical device company clients. Our qualified staff specializes in complex 3D cell-based assays to deliver standardized and custom in vitro models that better predict human response to drugs and devices. Contact: SCRA Micki Howard MacNaughton, 843-760-3329 Mobile: 843-697-9226 firstname.lastname@example.org
SC Launch Company, KIYATEC Inc., Receives Grainger Grant
Press spacebar to pause and continue. Press esc to stop.